Recital 125, Decision_act (EU) 2018/9019

In forcesince 29 Oct 2018

If Mars' competitors' revenue streams are reduced upstream, the Commission

considers that the merger may reduce their ability and incentive to invest in cost reduction, R&D and product quality.136 This is particularly the case for the smaller competitors such as Dechra, Spectrum and Virbac, whose sales are

131 Response to RFI to Competitors, question 4.

132 Responses to Q1 - Questionnaire to Veterinarians, question 17.

133 Non-Horizontal Merger Guidelines, paragraph 72.

134 Response to RFI to Competitors, questions 19 and 20.

135 Response to RFI to Competitors, questions 19 and 20.

136 Non-Horizontal Merger Guidelines, paragraph 65. significantly lower than Mars or Hill's. The Commission considers that the weakening of these competitors or their exit from the market may result in a loss of choice and of price competition in the upstream market, thereby enabling the merged entity to profitably raise prices in the downstream market.137